AZAFAROS

Azafaros is supported by a syndicate of leading Dutch and Swiss investors. Our clinical candidate AZ-3102 is an orally available azasugar designed to treat the central nervous system and to interfere with the metabolism of glycosphingolipids affecting key disease pathways through a unique dual mode of action... We are Azafaros. A beacon for people living with severe rare metabolic disorders. Azafaros is supported by a syndicate of leading Dutch and Swiss investors... Azafaros aims to be a beacon for patients living with severe rare genetic diseases and their families.

Also known as: Azafaros AG, Azafaros B.V.

Primary location: Naarden Netherlands